echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > JPD: Exhaled gas analysis of patients with Parkinson's disease, helpful for disease diagnosis and classification

    JPD: Exhaled gas analysis of patients with Parkinson's disease, helpful for disease diagnosis and classification

    • Last Update: 2022-04-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    With significant advances in the understanding of the underlying biological mechanisms of Parkinson's disease (PD), improvements in clinical diagnosis, stratification, and long-term monitoring of the disease remain key areas for further investigation
    .
    These questions become even more relevant as more and more clinical trials are conducted in search of potentially disease-modifying treatments

    .

    In addition, numerous longitudinal studies have also demonstrated significant heterogeneity in disease progression rates and clinical characteristics in PD populations
    .
    Therefore, while efforts are made to move towards more personalized and targeted PD therapy, better methods for diagnosing, evaluating, and monitoring PD patients are urgently needed

    .

    Extensive collaborative efforts are currently underway to identify biomarkers that can achieve this goal
    .
    However, many of these investigations involve invasive methods (such as lumbar puncture analysis of cerebrospinal fluid), do not provide immediate clinical feedback, and often involve specialized laboratory-based analysis and/or methods that are expensive and uncomfortable for the patient (such as MRI) or PET imaging)

    .

    Therefore, any new biomarker method for assessing PD patients, including methods that are rapid, easy to use and non-invasive, would have clear advantages
    .
    One way is by analyzing the breathing of patients with the disease

    .

    In this regard, the analysis of volatile organic compounds (VOCs) in breath has led to the development of technologies that can be used to identify, screen and longitudinally monitor chronic diseases such as PD
    .
    This approach has been successfully tested preclinically in neurotoxin-based PD models and transgenic PD models

    .
    In addition, in several small clinical studies, breath analysis has shown that this technique can distinguish not only idiopathic PD from healthy controls, but also PD from other Parkinson's syndromes and Alzheimer's disease, regardless of medication treatment

    .

    With this, Simon Stotta et al.
    , University of Cambridge, sought to extend these findings by studying a large, well-characterized clinical cohort of PD patients to determine whether the analysis of VOCs in breath samples could be used

    .
    1) confirm its diagnostic utility, including feasibility; 2) stage the disease; and 3) provide new or confirm established mechanistic insights into the condition

    .

    They collected breath samples from 177 PD patients and 37 healthy matched controls and followed them long-term
    .
    Standard clinical data (MDS-UPDRS and cognitive assessments) of PD patients were also collected at the same time as breath samples were collected, and these measures were then correlated with breath test analysis of exhaled VOCs

    .

    They found that breath testing was able to distinguish PD patients from healthy control participants and correlated with disease stage
    .
    The offline system (remote analysis) gave good results, with overall classification accuracy ranging from 73.
    6% to 95.
    6% across a range of clinical measures

    .

    Breath testing distinguishes PD patients from healthy control participants and correlates with disease stage

    Online (clinic) systems showed similar results, but with lower correlations ranging from 33.
    5% to 82.
    4%

    .
    Chemical analysis identified 29 distinct potential molecules that may be involved in the pathogenic pathways of PD

    .

    The significance of this study is the discovery that breath analysis shows potential for PD diagnosis and monitoring
    .
    Both off-line and on-line sensor systems are easy to operate and provide comparable results, which, if larger-scale studies corroborate our findings, will make this technology readily available for clinical adoption

    .

    Breath analysis shows potential for PD diagnosis and monitoring





    Original source:
    Stott S, Broza YY, Gharra A, Wang Z, Barker RA, Haick H.
    The Utility of Breath Analysis in the Diagnosis and Staging of Parkinson's Disease.
    _JPD_.
    Published online February 8, 2022:1-10.
    doi: [10.
    3233/JPD-213133](https://doi.
    org/10.
    3233/JPD-213133)




    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.